Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Enomoto, T. Takemura, T. Iwasawa, Y. Fukuda, N. Yanagawa, F. Sakai, T. Baba, E. Hagiwara, T. Ogura (Yokohama, Tokyo, Saitama, Japan). Prognostic factors of interstitial lung disease associated with primary Sjögren's syndrome. Eur Respir J 2013; 42: Suppl. 57, 2340

Member's Comments

No comment yet.

Related content which might interest you: The prognostic factor in patients with myositis-associated interstitial lung disease Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Study of factors affecting mortality in ILD cases over 2 years Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Clinical characteristics of 30 patients with interstitial pneumonia associated with anti-aminoacyl-tRNA-synthetase antibodies Source: International Congress 2016 – Connective tissue disorders Year: 2016 The role of detection of myositis specific and associated antibodies in Japanese patient with interstitial lung disease Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 Clinical analysis of lung manifestation in Sjögren's syndrome Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Significance of histopathologic features suggesting connective tissue disease in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Prognostic relevance of histologic features in nonspecific interstitial pneumonia (NSIP) Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Rituximab in severe, progressive interstitial lung disease Source: International Congress 2016 – Connective tissue disorders Year: 2016 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015 Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Metabolic syndrome in interstitial lung diseases Source: International Congress 2015 – IIPs: orphan Year: 2015 Significance of connective tissue disease features in idiopathic interstitial pneumonia Source: Eur Respir J 2012; 39: 661-668 Year: 2012